R&D Senior Management Leader

Nkere Kanu Ebube, Ph.D.

SUMMARY

Goal-oriented senior management leader with over 15 years experience with the pharmaceutical/biotech companies in dosage form design, formulation and process development, technical operations and technology transfer. Extensive experience in developing various dosage forms including oral solids, liquids, and semi-solids for branded, generic, OTC and nutraceutical products. Strong skills in team building/motivation and employee development, and possesses outstanding knowledge of product development regulations. Strengths include strong leadership and technical skills, multi-disciplinary background, creativity, problems solving skills, excellent communication and adapting to change.

Core competencies include:

• Scale-up & technology transfer • Process improvement/cost saving

• Controlled substance – DEA compliance

• Business development • CMC expertise – IND, NDA, ANDA

• Project management

Exceptional skills include:

• Fluid bed processing - particle coating • Tablets - bi-layer, chewable & ODTs

• Pan coating – film & enteric coating

• Bio-enhancement techniques

• Encapsulation – capsules, microspheres

• Drug delivery - controlled release • Granulation

• Extrusion & spheronization

• Suspensions & nano-particles

• Ion-exchange technology

PROFESSIONAL EXPERIENCE

King Pharmaceuticals, Inc., Piscataway, New Jersey 1/09 – 3/09

(King acquired Alpharma in January 2009)

Director, Technical Operations, 1/09 – 3/09

Responsible for technology transfer of new and existing products to 3rd party contract manufacturing sites, operation of R&D pilot plant, and support of regulatory filings and business development programs.

Accomplishments:

• Actively participated in the review of Alpharma/King Pharmaceuticals product portfolio, and functional integration of corporate operations following merger of the two companies.

• Provided leadership for the successful technology transfer and validation of EMBEDA®, extended release morphine sulfate capsules with abuse deterrent properties.

• Initiated and successfully executed program for evaluation of surrogates for opioid agonist and antagonist, which resulted in improved process, scale up and technology transfer with cost saving of over $1M and enhancement of product development lead time.

Alpharma Pharmaceuticals LLC, Piscataway, New Jersey 05/07 – 1/09

Director, Technical Operations, 5/07 – 1/09

Responsible for establishment, qualification and operation of R&D pilot plant, scale up and technology transfer of oral controlled release opioid solid dosage forms to 3rd party commercial manufacturing sites, supported regulatory submissions and business development programs.

Accomplishments:

• Developed a managed risk-based technology transfer process to improve product development lead times.

• Successfully scaled-up and completed technology transfer of two controlled release abuse deterrent opioid oral solid dosage forms to commercial manufacturing sites.

• Received sNDA approval for an extended release capsules, and successfully submitted NDA for a controlled release capsule based on abuse deterrent technology platform.

• Initiated New Product Concept and Technology Platform to secure core products franchise, seek opportunities for IP protection, identify new product and technology opportunities, and enhance corporate product portfolio.

• Created professional development opportunities for technical and non-technical staff in Technical Operations.

• Presented at the first annual convention of NAPPSA held in Houston, Texas on October 14-16, 2007 – “Outsourcing of Pharmaceutical Development: A Risk-Based Approach to Improve Lead Times.”

• Invited guest speaker at the 7th Contract Manufacturing for Pharmaceuticals, Philadelphia, Nov. 27-29, 2007.

• Invited speaker, Quality and Lean Conference organized by CPM, May 2008. Topic of presentation – “Best Practices for Improving Lead Time of Technology Transfer to CMOs.”

• Managed 5 senior process engineers, a technical operation technician, and a manager.

Biovail Technologies, Chantilly, Virginia 12/05 – 03/07

Associate Director, Formulation Development, 12/05 – 03/07

Responsible for development of over 10 NDAs oral controlled release dosage forms (including combination products), ANDAs, evaluation of new product development opportunities, manufacture of clinical supplies, and closely interfacing with IP group, business development and other cross-functional areas.

Accomplishments:

• Provided leadership for successful completion of eight phase-one studies from concept to pilot PK studies within 11-month period.

• Achieved aggressive timeline to develop an ANDA product with strong IP potential within 5 weeks; pivotal scale, biostudy and ANDA filing was targeted for 2Q07.

• Inaugurated cross-functional strategic planning tools to facilitate communication and speed up product development process.

• Instituted and implemented processes to enhance technical and professional development of personnel, and also generated templates to improve the standard of technical documents, reports and submission documents.

• Contributed to a book chapter on “Intelligent Preformulation Design and Predictions using Artificial Neural Networks,” submitted for publication in 2006.

• Invited as a guest scientist to the 40th Anniversary of Gatteffosse Scientific Meeting on “Influence of Lipid Excipients on Oral Drug Absorption” in France. (2006).

• Managed 12 scientists including an R&D Manager and a Sr. Spectroscopist.

Morton Grove Pharmaceuticals, Inc., Vernon Hills, Illinois 02/04 – 09/05

Director, Oral Controlled Release Technologies, 02/04 – 09/05

Responsible for establishing the oral controlled release and the liquid companion programs (infrastructure, personnel & selection of product portfolios), supporting the core product group, coordinating R&D Stability/DEA programs, and leading the development of 3 ANDAs and 1 NDA oral controlled release liquid products including generation of required CMC documents in support of regulatory submissions. Provided updates to Senior Corporate Management and Board of Directors.

Accomplishments:

• Completed feasibility development, reformulation and scale-up of phenytoin oral suspension with improved process and product attributes.

• Initiated and supervised the development of 3 ANDAs and 1 NDA oral controlled release liquids products – including generation of preliminary CMC documents (components & composition, raw materials – API & inactive ingredients, manufacturing facility & process, etc.), and identification of potential commercial manufacturing sites.

• Actively involved in seeking business development opportunities and partnerships to enhance MGP technology base.

• Encouraged scientific excellence and professional development by organizing technical presentations & reviews.

• Managed up to 10 scientists – 8 Ph.Ds and 2 MS scientists

Wyeth Consumer Healthcare, Richmond, Virginia. 02/98 – 02/04

R&D Manager, Formulation Development, 2001 – 2004

Manage the development of various liquids, semi-solid and solid dosage forms from concept to commercialization. Identify and qualify new commercial manufacturing sites, and lead technology transfer efforts. Support new product development initiatives, and corporate business development programs.

Accomplishments:

• Led a team of scientists to develop over 30 new solid dosage form and softgel products from product design, lab-scale to commercialization/launch phases. All products were successfully launched on schedule – First Quarter, 2001.

• Controlled Release Technology Evaluation Team: Reviewed strategies for commercializing new controlled release technologies/products through evaluation of preformulation, formulation, biopharmaceutics, and contract manufacturing components.

• Evolved a mechanism to develop and evaluate new product concepts in specific areas through a cross-functional team approach (i.e., Statistics, Preformulation, Formulation, Analytical, QA, Regulatory Affairs, and Business unit).

• Evaluated new technologies/product ideas as member of Global New Idea Review Team.

• Identified and evaluated critical raw materials, packaging and manufacturing process parameters to achieve optimum product design requirements for various products.

• Supervised/generated appropriate product development documents - technology transfer dossiers (product development reports, formula reports, product evaluation protocols & reports, batch records, process validation protocols & reports) and submission dossiers (CMC section – including full description of the drug substance, drug product & manufacturing process).

• Filed two patent applications on nano-particulate technology & novel chewable matrix.

• Recipient of Wyeth Consumer Healthcare Service Award

• Completed the development and launch of 2 Robitussin liquid products, 2 cough drops, 1 topical product, 1 liquigel product, IND for a suspension product, and manufacture of clinical supplies for an NDA product.

Whitehall Robins Healthcare, Richmond, Virginia 1998 – 2001

(Division was re-named Wyeth Consumer Healthcare in 2001)

Principal Scientist, Formulation Development, 2000 - 2001

Provide scientific leadership for the development of various oral liquids, topical, semi-solid, and tablet products. Supervised and trained junior research scientists on product development process. Participated in weekly quality team meetings, and generated batch records, protocols and other required documents to support product development activities.

Accomplishments (2000 Whitehall-Robins Excellence Award):

• Within 12 months, designed and developed 2 oral solid dosage products (A Centrum multi-vitamin product and Flexagen), which launched in 1999/2000.

• Received personal commendation letter from President of Whitehall-Robins for scientific contributions

• Filed one patent application on novel tablet coating technique.

Senior Scientist, Formulation Development, 1998 - 2000

Responsible for development of two nutraceutical products and various exploratory research projects to identify matrices for chewable tablets, and for oral controlled release tablets. Train research scientists, and technicians on product development process, and good laboratory practices. Sub-team leader for respiratory products responsible for routine project management and periodic updates to R&D senior management. Generate batch records, protocols and other required documents to support product development activities.

Accomplishments (1999 Whitehall-Robins Excellence Award):

• Completed product development of a solid dosage form proposed for future launch.

• Submitted 4 patent applications, which include:

1. Development of a new tablet coating technique

2. Simultaneous processing of multiple ingredients to improve content uniformity, lower processing time, enhance tablet properties, and save cost.

3. Technique for mal-odor removal.

4. Densification and improvement of compressibility of poorly compressible actives.

Florida A&M University, Tallahassee, FL 1996-1998

Asst Professor, Division of Basic Pharmaceutical Sciences, College of Pharmacy

Responsibilities:

• Taught both graduate courses (Controlled Drug Delivery and Advanced Physical Pharmacy) and undergraduate courses, such as Pharmaceutics I and II, and Pharmaceutical Analysis.

• Satisfied the promotional requirements for Associate Professor and tenure within two years.

Extracurricular Appointments:

• Member of College of Pharmacy Library and Drug Information Committee.

• Member of College of Pharmacy Continuing Education: Symposium and Seminar Committee.

• Member of College of Pharmacy Merit Criteria Review Committee.

Honors and Awards for Publication and Research Contributions

• Junior Research Investigator Enhancement Travel Award, Association of Minority

Health Professions Schools (AMHPS) - October 21-31, 1996.

• Junior Research Investigator Enhancement Travel Award, Association of Minority

Health Professions Schools (AMHPS) - November 1-6, 1997.

• Outstanding Recognition Award for teaching and research, College of Pharmacy,

Florida A&M University, 1998.

• Visiting Scientist, Sanofi Research, Philadelphia, PA, 1997.

Accomplishments:

• In 2 years, generated 6 publications on preformulation, design and development of novel drug delivery systems. Published articles include:

 “Effect of Drug, Formulation and Process Variables on Granulation and Compaction Characteristics of Heterogeneous Matrices: Part 11. HPMC and PVP Systems,” Drug Development & Industrial Pharmacy. 22(7), 561-567 (1996).

 “Sustained Release of Acetaminophen from Heterogeneous Matrix Tablets; Influence of Polymer Ratio, Polymer Loading, and Co-active on Drug Release,” Pharmaceutical Development and Technology, 2(2), 161-171 (1997).

 “Relating Formulation Variables to In Vitro Dissolution Using and Artificial Neural Network,” Pharmaceutical Development and Technology, 2(3), 1-8 (1997).

 “Formulation Characteristics of Ofloxacin Microspheres for the Treatment of Osteomylitis,” Proceedings of the International Symposium of Controlled Release Bioactive Materials. Mater, 24:783784 (1997).

 “Effect of Drug, Formulation and Process Variables on Granulation and Compaction Characteristics of Heterogeneous Matrices: Part 1. HPMC and HPC Systems,” International Journal of Pharmaceutics, 156, 49-57 (1997).

 “Comparative Dissolution Studies of Mefenamic Acid-Polyethylene Glycol Solid Dispersion Systems and Tablets,” Pharmaceutical Development and Technology, 3, 405-412 (1998).

• Secured nearly $1 million in research grants, which included:

 Utility of Artificial Intelligence in Design and Development of Sustained Release Ketoprofen Dosage Form. RCMI/IRC (1996/97).

 Long-acting Biodegradable Injectable Binary System for the Treatment of Alzheimer’s Disease. NIH (MBRS), 1998-2001.

 Long-acting Biodegradable Binary System for Alzheimer’s Disease. NIH (RCMI), 1998-2002.

University of Tennessee, Memphis, TN 1995

Postdoctoral Research Fellow, Department of Pharmaceutical Sciences, College of Pharmacy

• Formulated and developed pharmaceutical dosage forms, including tablets and granules. Used both wet and melt pelletization techniques with a High Shear Mixer-Granulator and a Computerized Data Collection System.

• Optimized controlled release dosage forms using Artificial Neural Networks.

• Developed non-destructive analytical techniques for determining physical properties and chemical constituents of tablets using Near Infrared Spectroscopy.

• Determined intra-tumoral drug distribution following administration of a controlled release injectable, biodegradable gel.

University of Mississippi, Oxford, MS 1990 - 1994

Laboratory Instructor, Department of Pharmaceutics, 1991-94

• Demonstrated tablet manufacturing techniques by wet granulation and direct compression processes to pharmacy student in the laboratory.

• Presented pre-laboratory lectures on the compounding of emulsions, suspensions, ointments and capsules to the first-year undergraduate pharmacy students.

Research Asst, Research Institute of Pharmaceutical Sciences (RIPS), 1990-94

• Performed assay method development and validation, stability studies and microbiological analysis of various pharmaceutical active ingredients.

Schering-Plough Incorporated, Memphis, TN May-August 1993

Graduate Summer Intern

• Performed Preformulation studies and evaluation of polymeric systems for sustained release formulations.

• Assisted in the design, manufacture and in vitro evaluation of matrix-type sustained release tablets formulated with various polymeric excipients.

EDUCATION / TRAINING

Ph.D, Pharmaceutics, University of Mississippi, Oxford, Mississippi

M. Pharm, Pharmaceutics, University of Nigeria, Nsukka, Nigeria.

B. Pharm, Pharmacy, University of Nigeria, Nsukka, Nigeria.

Professional Development courses or certifications

• Foundation of Leadership, Center for Creative Leadership, San Diego, CA

• Program on Technology Negotiation, A University Consortium - Harvard University, MIT & Tufts University

• Fundamentals of Finance for Technical Executive, Sloan School of Management, Massachusetts Institute of Technology (MIT).

ADDITIONAL RELEVANT INFORMATION

Professional Affiliations

• American Association of Pharmaceutical Scientists (AAPS)

• American Association of Colleges of Pharmacy (AACP)

• Controlled Release Society (CRS)

Publications/Presentations

(See attached selected publications, presentations, and patents)

PUBLICATIONS

1. N.K. Ebube. "Malaria: A Disease yet to be Conquered," Pharmanews, vol. 13, no. 1,

January 1991.

2. N.K. Ebube, O.K. Udeala and A.A. Ghobashy. "Isolation and Characterization of a Novel Polysaccharide from Bacillus licheniformis NCIB 11634," J. Ind. Micro., 9, 239-245 (1992).

3. N.K. Ebube, A. Hikal, C. Wyandt, C. Beer, L. Miller and A.B. Jones. "Effect of Drug, Formulation and Process Variables on Granulation and Compaction Characteristics of Heterogeneous Matrices: Part 11. HPMC and PVP Systems," Drug Dev Ind. Pharm. 22 (7), 561-567 (1996).

4. N.K. Ebube, A. Hikal, C. Wyandt, C. Beer, L. Miller and A.B. Jones. "Sustained Release of Acetaminophen from Heterogeneous Matrix Tablets: Influence of Polymer Ratio, Polymer Loading, and Co-active on Drug Release," Pharm. Dev. and Technol., 2 (2), 161-171 (1997).

5. N.K. Ebube, T. McCall, Y. Chen and M.C. Meyer. “Relating Formulation Variables to In Vitro Dissolution Using an Artificial Neural Network,” Pharm. Dev. and Technol., 2(3), 1-8 (1997).

6. G. Owusu-Ababio, S. Onyilofor, M. Habib and N.K. Ebube. “Formulation Characteristics of Ofloxacin Microspheres for the Treatment of Osteomylitis,” Proceed, Int. Symp, Controlled Rel. Bioact. Mater, 24: 783784 (1997).

7. N.K. Ebube, A. Hikal, C. Wyandt, C. Beer, L. Miller and A.B. Jones. "Effect of Drug, Formulation and Process Variables on Granulation and Compaction Characteristics of Heterogeneous Matrices: Part 1. HPMC and HPC Systems," Int. J. Pharm., 156, 49-57 (1997).

8. G. Owusu-Ababio, N.K. Ebube, R. Reams and M. Habib. "Comparative Dissolution Studies for Mefenamic Acid-Polyethylene Glycol Solid Dispersion Systems and Tablets,” Pharm. Dev. and Technol., 3, 405-412 (1998).

9. N.K. Ebube, A.J. Shukla , S.S. Thorsar, R. Roberts, M.S. Kemper, D. L. Martin, G. E. Reier and T.A. Wheatley. "Application of Near Infrared Spectroscopy (NIRS) for Non-Destructive Analysis of Avicel Powders and Tablets,” Pharm. Dev. and Technol., 4, 19-26 (1999).

10. M. Habib, S. Onyilofor, N.K. Ebube and G. Owusu-Ababio. “Preparation and Characterization of Ofloxacin Microspheres for the Eradication of Bone Associated Bacterial Biofilm,” J. Microencapsulation, 16: 27-37(1999).

11. N.K. Ebube, G. Owusu-Ababio and C.M. Adeyeye. "Preformulation Studies and Non-destructive Characterization of the Physicochemical Properties of Amorphous Polymers using Artificial Neural Networks," Int. J. Pharm., 196: 27-35 (2000).

12. Q. Yang, D. Williams, G. Owusu-Ababio, M.J. Habib and N.K. Ebube. “Controlled Release Tacrine Delivery System for the Treatment of Alzheimer’s Disease,” Drug Delivery, 8: 93-98 (2001).

13. N.K. Ebube, H. Hahm and W. Mark. “Preformulation Studies and Characterization of Two Chondroprotective Agents: Glucosamine HCl and Chondroitin Sulfate,” Pharm. Dev. And Technol., 7 (4), 457-469 (2002).

14. N.K. Ebube and A.B. Jones. "A Sustained Release of Acetaminophen from Heterogeneous Mixture of Two Hydrophilic Non-Ionic Cellulose Ether Polymers", Int. J. Pharm. 272, 19-27 (2004).

15. N.K. Ebube and A.B. Jones. "Preformulation Studies of Heterogeneous Matrices as Drug Delivery Carriers using a Mixture of HPMC and HPC or PVP", (unpublished article).

16. N.K. Ebube, A.J. Shukla, S.S. Thorsar, R. Roberts, M. Lyles, G. E. Reier and Wheatley. "Effect of Different Lubricants on Compression Properties of Various Grades of Avicel," (unpublished article).

17. N.K. Ebube, W. Wilson, W. William, A. Usayapant, C. Summitt, C. Kish and N. Partridge. “Effects of Drug, Processing and Formulation Variables on Release from Matrix Tablets Containing HPMC and Chondroitin Sulfate,” (unpublished article).

BOOK CHAPTER

N.K. Ebube. “Intelligent Preformulation Design and Predictions using Artificial Neural Networks” in: Preformulation in Solid Dosage Form Development, M.C. Adeyeye and H.G. Brittain, eds., Informa Health Care, NY, pages 81 – 114 (2008).

ABSTRACTS

"Evaluation of the Effect of Different Lubricants on the Compression Characteristics of

Various Grades of Avicel", N.K. Ebube, A.J. Shukla, S.S. Thorsar, R. Roberts, M.

Lyles, G. Reier and T. Wheatley. Presented at the American Association of

Pharmaceutical Scientist (AAPS) Conference in Miami, Florida, November 1995.

"Non-Destructive Determination of Tablet Crushing Strength and Lubricant Concentration using Near Infrared Spectroscopy", N.K. Ebube, A.J. Shukla, S.S. Thorsar, R. Roberts, D. Martin, M. Kemper, G. Reier and T. Wheatley. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Miami, Florida, November 1995.

"Application of Artificial Intelligence to Pharmaceutical Product Development: A Systematic Approach to the Selection of Training Data", N.K. Ebube, M.C. Meyer and T. McCall. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Miami, Florida, November 1995.

"Non-Destructive Analysis of Physical and Chemical Characteristics of Tablets by Near Infrared Transmission Spectroscopy", R.L Rubinovitz, W. M. Trygstad, A.J. Shukla, N. K. Ebube, G. E. Reier and T.A. Wheatley. Presented at the Eastern Analytical Symposium (EAS), Somerset, NJ, November 1995.

"Effect of Varying Concentrations of Different Lubricants on Compression Characteristics of Various Grades of Avicel, R. Roberts, S. S. Thorsar, A. J. Shukla, N. K. Ebube, G. E. Reier and T.A. Wheatley. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Seattle, Washington, October 1996.

"Non-Destructive Determination of Drug Content in Intact Tablets Using Near Infrared Spectroscopy", S.S. Thorsar, R. Roberts, A.J. Shukla, N.K Ebube, R.L. Rubinovitz, M.Kemper, G.E. Reier and T. A. Wheatley. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Seattle, Washington, October 1996.

"Non-Destructive Characterization of the Physicochemical Properties of Amorphous Polymers Using the Artificial Neural Networks", N.K. Ebube, G. Owusu-Ababio and R.G. Alamo. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Seattle, Washington, October 1996.

"Formulation Characteristics of Ofloxacin Microspheres for the Treatment of Osteomylitis", G. Owusu-Ababio, S. Onyalifor, M. Habib and N.K. Ebube. Presented at the Controlled Release Society Meeting, Stockholm, Sweden, June 1997.

"Formulation and Optimization of Encapsulation Efficiency of Monensin Liposomes Using the Artificial Neural Networks", N.K. Ebube, S. Bennefield, A.J. Ferdous and M. Singh. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Boston, Massachusetts, November 1997.

"Data-Driven Design of Experiments Using Artificial Intelligence: Implication for Formulation Development", N.K. Ebube, G. Owusu-Ababio and C.M. Adeyeye. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Boston, Massachusetts, November 1997.

"Optimization of Pharmaceutical Unit Operations Using the Artificial Neural Networks", N.K. Ebube and C.M. Adeyeye. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Boston, Massachusetts, November 1997.

"Poly (Glycolic Acid-Co-DL-Lactic Acid) Microspheres of Enoxacin for Treatment of Bacterial Biofilm Infections", G. Owusu-Ababio, N. K. Ebube, S. Ademuyiwa, M. Sachdeva and M.J. Habib. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Boston, Massachusetts, November 1997.

"Biodegradable Amoxicillin Microparticles for Treatment of Bacterial Biofilm.” M.J. Habib, S. Onyilofor, N.K. Ebube, G. Owusu-Ababio. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Boston, Massachusetts, November 1997.

“Prediction of Tablet Drug Content and Hardness using the Artificial Neural Network (ANN) and Near-Infrared Spectroscopy (NIRS).” Yixin Chen, S.S. Thosar, R.A. Roberts, M.S. Kemper, R. Rubinovitz, N.K. Ebube and A.J. Shukla. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in San Francisco, California, November 1998.

“Biodegradable Progesterone Delivery System for Osteoporosis Therapy.” Godfried Owusu-Ababio, Qing Yang, Nkere Ebube, and Muhammad Habib. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in San Francisco, California, November 1998.

“Effects of Drug, Processing and Formulation Variables on Release from Matrix Tablets Containing HPMC and Chondroitin Sulfate.” N.K. Ebube, W. Wilson, W. William, A. Usayapant, C. Summitt, C. Kish and N. Partridge. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Denver, Colorado, October 2001.

“Preformulation Studies and Characterization of Two Proposed Chondroprotective Agents: Glucosamine HCl and Chondroitin Sulfate.” N.K. Ebube, W. William and H. Hahm. Presented at the American Association of Pharmaceutical Scientist (AAPS) Conference in Denver, Colorado, October 2001.

“Optimization of Sustained Release Matrix Tablet Formulations Containing HPMC and Chondroitin Sulfate Using Artificial Neural Networks (ANNs).” N.K. Ebube, Wendy I. Wilson and Neil Partridge. Presented at the American Association of Pharmaceutical Scientists Annual Conference, Toronto, Canada (November 2002).

“Comparison of Statistical and Artificial Neural Network Methods for Formulation Optimization: Application to Sustained Release Matrix Tablets Containing Carrageenan and Sodium Alginate.” N.K. Ebube, Wendy I. Wilson and Neil Partridge. Presented at the American Association of Pharmaceutical Scientists Annual Conference, Toronto, Canada (November 2002).

“Effect of pH on the Physical and Rheological Properties of Avicel-Xanthan Suspensions.” N.K. Ebube, Lili-Wang-Tsang, Hanife Akin, Sandra Jordan, Kenneth Hall, and Todd Koch. Presented at the American Association of Pharmaceutical Scientists Annual Conference, Toronto, Canada (November 2002).

“Effect of Aging and Temperature on the Physical and Rheological Properties of Avicel-Xanthan Suspensions.” N.K. Ebube, Lili-Wang-Tsang, Hanife Akin, Sandra Jordan, and Todd Koch. N.K. Ebube, Lili-Wang-Tsang, Hanife Akin, Sandra Jordan, and Todd Koch. Presented at the American Association of Pharmaceutical Scientists Annual Conference, Toronto, Canada (November 2002).

“Solubility of Dextromethorphan in Non-Aqueous Solvents.” P.T. Mayer, J.W. Hutcheson, J.N. Phillips, N.K. Ebube and T.S. Koch. Presented at the American Association of Pharmaceutical Scientists Annual Conference, Toronto, Canada (November 2002).

“Preformulation Studies and Prediction of Dosage Form Performance Using Artificial Neural Networks – Case Studies.” N.K. Ebube, Wendy Wilson and Neil Partridge. Presented at the American Association of Pharmaceutical Scientists Annual Conference, Salt Lake City, Utah (October 2003).

INVITED PRESENTATIONS

"Preformulation Studies of Matrix-Type Sustained Release Tablets," Presented at TIMERX Technologies, Patterson, NY, January 1995.

"Systematic Approach to Design and Optimization of Pharmaceutical Dosage Form using Neural Networks," Presented at TIMERX Technologies, Patterson, NY, July 1995.

"Drug Release for Swelling Polymeric Matrix Devices," Presented at Department of Chemical Engineering, FSU/FAMU School of Engineering, Tallahassee, Florida, November 1996.

"Formulation Modeling and Optimization with Neural Networks," Presented at Pharmaceutical Unit Processes and Solid Dosage Form Development Workshop, Duquesne University, Pittsburgh, PA, May 27-31, 1997.

"Future of Pharmacy Education: Impact on Pharmaceutical Industry," Presented at Sanofi Research, Philadelphia, PA, August 1997.

"Application of Artificial Neural Networks in Formulation Development," Presented at Sanofi Research, Philadelphia, PA, August 1997.

"Application of Artificial Intelligence in Pharmaceutical Product Development," Presented at University of Florida, Gainesville, FL, October 1997.

“Neural Network and Prediction of Tablet Dosage Form Performance – Case Study,” Presented at Pharmaceutical Unit Processes and Solid Dosage Form Development Workshop, Duquesne University, Pittsburgh, PA (May 18-21, 1998 & May 24-28, 1999).

“Prediction of Dosage Form Performance using Artificial Intelligence - Case Studies,” Presented at MCV College of Pharmacy, Richmond, VA (January 2002).

“Outsourcing of Pharmaceutical Development: A Managed Risk-Based Approach to Improve Lead Times,” Nigerian Association of Pharmacists and Pharmaceutical Scientists in America (NAPPSA), Houston, TX, September 14-16, 2007.

“Best Practices for Improving Lead Time of Technology Transfer to Contract Manufacturing Organization,” Quality and Lean Conference, Milan, Italy, May 2008.

Contact this candidate